Canadian Media Releases 2007

Novartis Canada Media Releases

2007 Media Releases

11/21/07	Novartis wins the 2007 Belleau-Nickerson Award for the cancer drug Gleevec

10/04/07	Novartis Pharmaceuticals Canada Inc. complies with request from Health Canada to withdraw Prexige in Canada

09/19/07	Team of recreational cyclists from Novartis ride from Toronto to Montreal and raise $90,000 for breast cancer research

09/18/07	First osteoporosis study in patients with hip fracture finds once-yearly Aclasta* prevents additional fractures and improves survival

05/15/07	Novartis Receives Health Canada Approval for First Fully Automated Nucleic Acid Testing Solution to Screen for West Nile Virus

05/14/07	Sandoz to invest $80 million in Quebec facilities

05/02/07	Once-yearly Aclasta shown to significantly reduce bone fractures in women with postmenopausal osteoporosis

04/30/07	Landmark study shows 40% reduction in cardiovascular events and stroke with Diovan Study halted early due to superior outcomes

04/27/07	Novartis Lends a Helping Hand on 11th Annual Community Partnership Day

04/13/07	Positive results from cancer study prompt the National Cancer Institute (NCI) to halt study early and offer Gleevec to all trial participants

	2006

	2005

	2004

	2003

	2002

Most of Novartis AG's "global" media releases are in English, French, and German. They can be searched by date or key words and there is a rich archive

Novartis Global Media Releases

DISCLAIMER FOR ARCHIVES
The information in our Media Release Archives was factually accurate on the date of publication. This information remains on our website for historical purposes only. Novartis Pharmaceuticals Canada Inc. assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon this information as current or accurate after their publication dates.